JAKi Regulatory Decisions - FDA, EMA, Canada
Nov 15, 2022
Oral Surveillance study resulted in a new FDA drug safety bulleting 9/21/21 and since the label for all JAK inhibitors has changed (FDA, Canada) or will change (EMA).
Oral Surveillance study resulted in a new FDA drug safety bulleting 9/21/21 and since the label for all JAK inhibitors has changed (FDA, Canada) or will change (EMA).
Use this resource to keep track of your clinical trials and key information needed when communicating with patients about a drug study.
Outcomes, misdiagnosis, diagnosis, Diagnostic criteria and treatmenet options for AOSD
Handouts to Dr. Len Calabreses TNR Presentation